Effect Of Rosuvastatin On PAPP-A,SICAM-1 And In-stent Restenosis In Patients With Coronary Heart Disease

ObjectTo investigate the effect of rosuvastatin on pregnancy-associated plasma protein-A(PAPP-A),Soluble Intercellular Adhesion Molecule–1(SICAM-1)and in-stent restenosis in patients with coronary heart disease,by observering the variation of plasma levels of PAPP-A and SICAM-1 with rosuvastatin therapy before and 1 week after percutaneous coronary intervention(PCI) and the occurrence of in-stent restenosis.Method78 patients,who were more than 75% stenosis(diameter method) by coronary arteriography(CAG),were randomly divided into rosuvastatin group and simvastatin group who were treated with rosuvastatin therapy and simvastatin therapy for 6 month after PCI, plasma levels of PAPP-A and SICAM-1 were determined before and 1 week after PCI.Restenosis related symptoms were observed in 6-month follow-up. CAGs were reexamined when the follow-up was over or symptoms appeared.Result(1) Compared to Control group,plasma levels of PAPP-A and SICAM-1 in both rosuvastatin group and simvastatin group were higher with statistically significant(p<0.01);No significant difference was found between rosuvastatin group and simvastatin group(p>0.05).(2) Plasma levels of PAPP-A and SICAM-1 were much higher 1day later than before PCI in rosuvastatin group and simvastatin group significantly(p<0.05); plasma levels of PAPP-A and SICAM-1 were much lower 1 week later than before PCI in rosuvastatin group and simvastatin group significantly(p<0.05);The decreasing of plasma levels of PAPP-A and SICAM-1 were significantly higher in rosuvastatin group than simvastatin group(p<0.05).(3) No significant difference was found between the occurrence of in-stent restenosis of rosuvastatin group and simvastatin group(p>0.05). Plasma levels of PAPP-A and SICAM-1 were higher significantly in those who with restenosis than those without(p<0.05)。(4) Plasma levels of PAPP-A were positively correlated with plasma levels of SICAM-1.Conclusion(1)Plasma levels of PAPP-A and SICAM-1 may be valuable predictors of infammatory and restenosis after PCI.(2) Rosuvastatin and simvastatin may reduce plasma levels of PAPP-A and SICAM-1. after PCI, but rosuvastatin may reduce more evidently the plasma levels of PAPP-A, SICAM-1 than simvastatin after PCI(3) Rosuvastatin and restenosis have been not yet clear after PCI, which need large-scale clinical trials confirm.